MX2022016179A - Compuestos y metodos para tratar infecciones fungicas. - Google Patents
Compuestos y metodos para tratar infecciones fungicas.Info
- Publication number
- MX2022016179A MX2022016179A MX2022016179A MX2022016179A MX2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A MX 2022016179 A MX2022016179 A MX 2022016179A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- fungal infections
- treating fungal
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040450P | 2020-06-17 | 2020-06-17 | |
| PCT/US2021/037578 WO2021257670A1 (en) | 2020-06-17 | 2021-06-16 | Compounds and methods for treating fungal infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016179A true MX2022016179A (es) | 2023-04-20 |
Family
ID=79268375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016179A MX2022016179A (es) | 2020-06-17 | 2021-06-16 | Compuestos y metodos para tratar infecciones fungicas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230233586A1 (https=) |
| EP (1) | EP4167998A4 (https=) |
| JP (1) | JP2023530936A (https=) |
| KR (1) | KR20230024375A (https=) |
| CN (1) | CN115884775A (https=) |
| AU (1) | AU2021293911B2 (https=) |
| BR (1) | BR112022024988A2 (https=) |
| CA (1) | CA3187268A1 (https=) |
| IL (1) | IL299057A (https=) |
| MX (1) | MX2022016179A (https=) |
| TW (1) | TWI888580B (https=) |
| WO (1) | WO2021257670A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010804A (es) | 2020-03-04 | 2023-01-16 | Amplyx Pharmaceuticals Inc | Uso de compuestos en el tratamiento de infecciones fungicas. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI385169B (zh) * | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| US8513287B2 (en) * | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| EP2636409A1 (en) * | 2010-11-05 | 2013-09-11 | Eisai R&D Management Co., Ltd. | Combined pharmaceutical composition as antifungal agent |
| WO2020047510A1 (en) * | 2018-08-31 | 2020-03-05 | Amplyx Pharmaceuticals, Inc. | Compounds and methods for treating fungal infections |
| US11819503B2 (en) * | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| MX2022010804A (es) * | 2020-03-04 | 2023-01-16 | Amplyx Pharmaceuticals Inc | Uso de compuestos en el tratamiento de infecciones fungicas. |
-
2021
- 2021-06-16 CA CA3187268A patent/CA3187268A1/en active Pending
- 2021-06-16 CN CN202180050716.0A patent/CN115884775A/zh active Pending
- 2021-06-16 WO PCT/US2021/037578 patent/WO2021257670A1/en not_active Ceased
- 2021-06-16 AU AU2021293911A patent/AU2021293911B2/en active Active
- 2021-06-16 MX MX2022016179A patent/MX2022016179A/es unknown
- 2021-06-16 KR KR1020237001328A patent/KR20230024375A/ko not_active Ceased
- 2021-06-16 JP JP2022577084A patent/JP2023530936A/ja active Pending
- 2021-06-16 IL IL299057A patent/IL299057A/en unknown
- 2021-06-16 EP EP21825864.8A patent/EP4167998A4/en active Pending
- 2021-06-16 BR BR112022024988A patent/BR112022024988A2/pt unknown
- 2021-06-16 US US18/002,012 patent/US20230233586A1/en active Pending
- 2021-06-17 TW TW110122166A patent/TWI888580B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3187268A1 (en) | 2021-12-23 |
| EP4167998A1 (en) | 2023-04-26 |
| JP2023530936A (ja) | 2023-07-20 |
| AU2021293911A1 (en) | 2023-01-19 |
| AU2021293911B2 (en) | 2024-11-14 |
| US20230233586A1 (en) | 2023-07-27 |
| KR20230024375A (ko) | 2023-02-20 |
| BR112022024988A2 (pt) | 2022-12-27 |
| WO2021257670A1 (en) | 2021-12-23 |
| EP4167998A4 (en) | 2024-07-17 |
| CN115884775A (zh) | 2023-03-31 |
| TW202214258A (zh) | 2022-04-16 |
| TWI888580B (zh) | 2025-07-01 |
| IL299057A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2018010966A2 (es) | Nuevos derivados de pirazolopirimidina | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CL2020001147A1 (es) | Compuestos antibacterianos | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| MX2024004874A (es) | Compuestos heterociclicos para uso en el tratamiento de cancer. | |
| CO2021014747A2 (es) | Métodos para el tratamiento de βeta-talasemia | |
| MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| CL2022002589A1 (es) | Tratamiento de trastornos respiratorios | |
| MX2022016179A (es) | Compuestos y metodos para tratar infecciones fungicas. | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
| CL2024002103A1 (es) | Métodos para tratar amiloidosis al |